Skip to content

Earnings yield at other companies

Eli Lilly logo
Eli LillyLLY
3.1%+1.6pp
Amgen logo
AmgenAMGN
4.1%+0.6pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-2.6%-1.1pp
Arrowhead Research logo
Arrowhead ResearchARWR
-3.4%-1.3pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-12.5%-0.7pp
Moderna logo
ModernaMRNA
-15.9%-5.2pp

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

Based on trailing twelve months.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's earnings yield?
Ultragenyx Pharmaceutical (RARE) reported earnings yield of -29.6% in Q1 2026.
How has Ultragenyx Pharmaceutical's earnings yield changed year-over-year?
Ultragenyx Pharmaceutical's earnings yield decreased by 83.0% year-over-year, from -16.2% to -29.6%.
What is the long-term trend for Ultragenyx Pharmaceutical's earnings yield?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's earnings yield has grown at a 67.3% compound annual growth rate (CAGR), from -2% to -25.9%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.